APOBEC3A and cancer: In addition, we further investigated the therapeutic responsiveness and clinical benefits to anti-PD-L1 immunotherapy by comparing different APOBEC3A expression cohorts, and cancer patients with high expression of APOBEC3A were found to have a more positive response to immunotherapy, thus a better clinical outcome (Figures 6C–E).